Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ACT-128800 in Healthy Subjects
Single-center, Double-blind, Placebo-controlled, Randomized, Parallel-group, Up-titration Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Increasing Doses of ACT-128800 in Healthy Male and Female Subjects
研究概览
研究类型
注册 (实际的)
阶段
- 阶段1
联系人和位置
学习地点
-
-
-
London、英国、SE1 1YR
- Quintiles Drug Research Unit at Guy's Hospital
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Inclusion Criteria:
- Signed informed consent in the local language prior to any study-mandated procedure.
- Age between 18 and 65 years (inclusive) at screening.
- Body mass index (BMI) between 18 and 30 kg/m^2 (inclusive).
- Women of childbearing potential were required to have a negative serum pregnancy test at screening and a negative urine pregnancy test prior to first drug intake and have agreed to use two methods of contraception from the screening visit until 2 months after study drug discontinuation.
- Systolic blood pressure 100-150 mmHg, diastolic blood pressure 50-90 mmHg measured on the leading arm, and heart rate 50-95 beats per minute (inclusive) measured by electrocardiography (ECG) after 5 minutes in the supine position at screening.
- ECG without clinically relevant abnormalities at screening.
- Hematology and clinical chemistry results not deviating from the normal range to a clinically relevant extent at screening.
- Negative results from urine drug screen at screening.
- Ability to communicate well with the investigator and to understand and comply with the requirements of the study.
Exclusion Criteria:
- ECG recording; PQ/PR interval > 200 ms at screening.
- Pregnant or lactating women.
- Known hypersensitivity to any excipients of the drug formulation.
- Known hypersensitivity to beta2 adrenergic receptor agonists.
- Veins unsuitable for intravenous puncture on either arm (e.g., veins that are difficult to locate, access or puncture; veins with a tendency to rupture during or after puncture).
- Treatment with another investigational drug within 3 months prior to screening.
- Excessive caffeine consumption, defined as ≥ 800 mg per day at screening. History or clinical evidence of any disease and/or existence of any surgical or medical condition that might interfere with the absorption, distribution, metabolism or excretion of the study drug.
- Smoking within the last month prior to screening.
- Any immunosuppressive treatment within 6 weeks before study drug administration.
- Previous treatment with any prescribed or over-the-counter medications (including herbal medicines such as St John's Wort) within 2 weeks prior to screening or 5 half-lives of the drug, whichever is longer.
- Loss of 250 mL or more of blood within 3 months prior to screening.
- Lymphopenia (< 1,000 cells/μL).
- Viral, fungal, bacterial or protozoal infection within 4 weeks before study drug administration (e.g., active herpes and/or cytomegalovirus infection).
- History or clinical evidence suggestive of active or latent tuberculosis at screening.
- Positive results from the hepatitis serology, except for vaccinated subjects, at screening.
- Positive results from the human immunodeficiency virus serology at screening.
- Forced expiratory volume in 1 second (FEV1) or forced vital capacity (FVC) < 80% of the predicted value, or FEV1/FVC ratio < 0.7 at screening.
- History of asthma or chronic obstructive pulmonary disease.
- Any cardiac condition or illness (including ECG abnormalities) with a potential to increase the cardiac risk of the subject in the standard 12-lead ECG and 24-hour 3-lead Holter ECG at screening.
- History of fainting, collapse, syncope, orthostatic hypotension, or vasovagal reactions.
- Familial history of sick-sinus syndrome.
- History or clinical evidence of alcoholism or drug abuse within the 3-year period prior to screening. Alcohol abuse is defined as regular weekly intake of more than 21 units.
- Legal incapacity or limited legal capacity at screening.
- Any circumstances or conditions, which, in the opinion of the investigator, may affect the subject's full participation in the study or compliance with the protocol.
学习计划
研究是如何设计的?
设计细节
- 分配:随机化
- 介入模型:并行分配
- 屏蔽:四人间
武器和干预
参与者组/臂 |
干预/治疗 |
---|---|
实验性的:ACT-128800
ACT-128800 tablets, once daily for 3 days at each dose level: 10 mg, 20 mg, 40 mg, 60 mg, 80 mg, and 100 mg.
|
|
安慰剂比较:Placebo
Matching placebo tablets, once daily, for 18 days
|
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
---|---|---|
Change from baseline to Day 18 in systolic blood pressure
大体时间:18 days
|
Blood pressure was measured using an automatic oscillometric device, always on the leading arm (i.e., leading arm right = writing with right hand). Measurements were recorded from the subject in the supine position after having rested for a 5-minute period. |
18 days
|
Change from baseline to Day 18 in diastolic blood pressure
大体时间:18 days
|
Blood pressure was measured using an automatic oscillometric device, always on the leading arm (i.e., leading arm right = writing with right hand). Measurements were recorded from the subject in the supine position after having rested for a 5-minute period. |
18 days
|
Change from baseline to Day 18 in pulse rate
大体时间:18 days
|
Pulse rate was measured using an automatic oscillometric device, always on the leading arm (i.e., leading arm right = writing with right hand). Measurements were recorded from the subject in the supine position after having rested for a 5-minute period. |
18 days
|
Change from baseline to Day 18 in body temperature
大体时间:18 days
|
Body temperature was measured in the supine position using the same thermometer throughout the study.
|
18 days
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
---|---|---|
Change from baseline to Day 10 in mean absolute lymphocyte count
大体时间:10 days
|
For each assessment, 1.5 mL of blood was collected aseptically from the subject in the supine position by venipuncture or via an intravenous.
catheter placed in an antecubital vein in the arm in ethylenediaminetetraacetic acid containing tubes.
Immediately following collection of the required whole blood volume, the tubes were slowly tilted backwards and forwards (no shaking) to bring the anti-coagulant into solution.
The anticoagulated whole blood stored at room temperature (20-25 °C) was preferably stained within 12 hours, at the latest 24 hours, and analyzed within 24 hours.
The lymphocyte counts were determined with standard commercially available assay kits.
|
10 days
|
Change from baseline to Day 10 in mean T cell (Cluster of differentiation (CD) CD3+) lymphocyte count
大体时间:10 days
|
For each assessment, 1.5 mL of blood was collected aseptically from the subject in the supine position by venipuncture or via an intravenous.
catheter placed in an antecubital vein in the arm in ethylenediaminetetraacetic acid containing tubes.
Immediately following collection of the required whole blood volume, the tubes were slowly tilted backwards and forwards (no shaking) to bring the anti-coagulant into solution.
The anticoagulated whole blood stored at room temperature (20-25 °C) was preferably stained within 12 hours, at the latest 24 hours, and analyzed within 24 hours.
The lymphocyte subset counts were analyzed by fluorescence activated cell sorting.
|
10 days
|
Change from baseline to Day 10 in mean B cell (CD3-/CD19+) lymphocyte count
大体时间:10 days
|
For each assessment, 1.5 mL of blood was collected aseptically from the subject in the supine position by venipuncture or via an intravenous.
catheter placed in an antecubital vein in the arm in ethylenediaminetetraacetic acid containing tubes.
Immediately following collection of the required whole blood volume, the tubes were slowly tilted backwards and forwards (no shaking) to bring the anti-coagulant into solution.
The anticoagulated whole blood stored at room temperature (20-25 °C) was preferably stained within 12 hours, at the latest 24 hours, and analyzed within 24 hours.
The lymphocyte subset counts were analyzed by fluorescence activated cell sorting.
|
10 days
|
Change from baseline to Day 10 in mean natural killer (NK) cell (CD3-/CD56+) lymphocyte count
大体时间:10 days
|
For each assessment, 1.5 mL of blood was collected aseptically from the subject in the supine position by venipuncture or via an intravenous.
catheter placed in an antecubital vein in the arm in ethylenediaminetetraacetic acid containing tubes.
Immediately following collection of the required whole blood volume, the tubes were slowly tilted backwards and forwards (no shaking) to bring the anti-coagulant into solution.
The anticoagulated whole blood stored at room temperature (20-25 °C) was preferably stained within 12 hours, at the latest 24 hours, and analyzed within 24 hours.
The lymphocyte subset counts were analyzed by fluorescence activated cell sorting.
|
10 days
|
Change from baseline to Day 10 in mean natural killer T (NKT) cell (CD3+/CD56+) lymphocyte count
大体时间:10 days
|
For each assessment, 1.5 mL of blood was collected aseptically from the subject in the supine position by venipuncture or via an intravenous.
catheter placed in an antecubital vein in the arm in ethylenediaminetetraacetic acid containing tubes.
Immediately following collection of the required whole blood volume, the tubes were slowly tilted backwards and forwards (no shaking) to bring the anti-coagulant into solution.
The anticoagulated whole blood stored at room temperature (20-25 °C) was preferably stained within 12 hours, at the latest 24 hours, and analyzed within 24 hours.
The lymphocyte subset counts were analyzed by fluorescence activated cell sorting.
|
10 days
|
Change from baseline to Day 10 in mean CD4+ T-helper cell (CD3+/CD4+) lymphocyte count
大体时间:10 days
|
For each assessment, 1.5 mL of blood was collected aseptically from the subject in the supine position by venipuncture or via an intravenous.
catheter placed in an antecubital vein in the arm in ethylenediaminetetraacetic acid containing tubes.
Immediately following collection of the required whole blood volume, the tubes were slowly tilted backwards and forwards (no shaking) to bring the anti-coagulant into solution.
The anticoagulated whole blood stored at room temperature (20-25 °C) was preferably stained within 12 hours, at the latest 24 hours, and analyzed within 24 hours.
The lymphocyte subset counts were analyzed by fluorescence activated cell sorting.
|
10 days
|
Change from baseline to Day 10 in mean T-cytotoxic cell (CD3+/CD8+) lymphocyte count
大体时间:10 days
|
For each assessment, 1.5 mL of blood was collected aseptically from the subject in the supine position by venipuncture or via an intravenous.
catheter placed in an antecubital vein in the arm in ethylenediaminetetraacetic acid containing tubes.
Immediately following collection of the required whole blood volume, the tubes were slowly tilted backwards and forwards (no shaking) to bring the anti-coagulant into solution.
The anticoagulated whole blood stored at room temperature (20-25 °C) was preferably stained within 12 hours, at the latest 24 hours, and analyzed within 24 hours.
The lymphocyte subset counts were analyzed by fluorescence activated cell sorting.
|
10 days
|
Change from baseline to Day 10 in mean CD4+T-naive cell (CD45RA+/chemokine receptor type 7 (CCR7+)) lymphocyte count
大体时间:10 days
|
For each assessment, 1.5 mL of blood was collected aseptically from the subject in the supine position by venipuncture or via an intravenous.
catheter placed in an antecubital vein in the arm in ethylenediaminetetraacetic acid containing tubes.
Immediately following collection of the required whole blood volume, the tubes were slowly tilted backwards and forwards (no shaking) to bring the anti-coagulant into solution.
The anticoagulated whole blood stored at room temperature (20-25 °C) was preferably stained within 12 hours, at the latest 24 hours, and analyzed within 24 hours.
The lymphocyte subset counts were analyzed by fluorescence activated cell sorting.
|
10 days
|
Change from baseline to Day 10 in mean CD4+ T-central memory cell (CD45RA-/CCR7+) lymphocyte count
大体时间:10 days
|
For each assessment, 1.5 mL of blood was collected aseptically from the subject in the supine position by venipuncture or via an intravenous.
catheter placed in an antecubital vein in the arm in ethylenediaminetetraacetic acid containing tubes.
Immediately following collection of the required whole blood volume, the tubes were slowly tilted backwards and forwards (no shaking) to bring the anti-coagulant into solution.
The anticoagulated whole blood stored at room temperature (20-25 °C) was preferably stained within 12 hours, at the latest 24 hours, and analyzed within 24 hours.
The lymphocyte subset counts were analyzed by fluorescence activated cell sorting.
|
10 days
|
Change from baseline to Day 10 in mean CD4+ T-effector memory cell (CD45RA-/CCR7-) lymphocyte count
大体时间:10 days
|
For each assessment, 1.5 mL of blood was collected aseptically from the subject in the supine position by venipuncture or via an intravenous.
catheter placed in an antecubital vein in the arm in ethylenediaminetetraacetic acid containing tubes.
Immediately following collection of the required whole blood volume, the tubes were slowly tilted backwards and forwards (no shaking) to bring the anti-coagulant into solution.
The anticoagulated whole blood stored at room temperature (20-25 °C) was preferably stained within 12 hours, at the latest 24 hours, and analyzed within 24 hours.
The lymphocyte subset counts were analyzed by fluorescence activated cell sorting.
|
10 days
|
Change from baseline to Day 10 in mean CD4+ T-effector cell (CD45RA+/CCR7-) lymphocyte count
大体时间:10 days
|
For each assessment, 1.5 mL of blood was collected aseptically from the subject in the supine position by venipuncture or via an intravenous.
catheter placed in an antecubital vein in the arm in ethylenediaminetetraacetic acid containing tubes.
Immediately following collection of the required whole blood volume, the tubes were slowly tilted backwards and forwards (no shaking) to bring the anti-coagulant into solution.
The anticoagulated whole blood stored at room temperature (20-25 °C) was preferably stained within 12 hours, at the latest 24 hours, and analyzed within 24 hours.
The lymphocyte subset counts were analyzed by fluorescence activated cell sorting.
|
10 days
|
Change from baseline to Day 10 in mean CD8+ T-naive cell (CD45RA+/CCR7+) lymphocyte count
大体时间:10 days
|
For each assessment, 1.5 mL of blood was collected aseptically from the subject in the supine position by venipuncture or via an intravenous.
catheter placed in an antecubital vein in the arm in ethylenediaminetetraacetic acid containing tubes.
Immediately following collection of the required whole blood volume, the tubes were slowly tilted backwards and forwards (no shaking) to bring the anti-coagulant into solution.
The anticoagulated whole blood stored at room temperature (20-25 °C) was preferably stained within 12 hours, at the latest 24 hours, and analyzed within 24 hours.
The lymphocyte subset counts were analyzed by fluorescence activated cell sorting.
|
10 days
|
Change from baseline to Day 10 in mean CD8+ T-central memory cell (CD45RA-/CCR7+) lymphocyte count
大体时间:10 days
|
For each assessment, 1.5 mL of blood was collected aseptically from the subject in the supine position by venipuncture or via an intravenous.
catheter placed in an antecubital vein in the arm in ethylenediaminetetraacetic acid containing tubes.
Immediately following collection of the required whole blood volume, the tubes were slowly tilted backwards and forwards (no shaking) to bring the anti-coagulant into solution.
The anticoagulated whole blood stored at room temperature (20-25 °C) was preferably stained within 12 hours, at the latest 24 hours, and analyzed within 24 hours.
The lymphocyte subset counts were analyzed by fluorescence activated cell sorting.
|
10 days
|
Change from baseline to Day 10 in mean CD8+ T-effector memory cell (CD45RA-/CCR7-) lymphocyte count
大体时间:10 days
|
For each assessment, 1.5 mL of blood was collected aseptically from the subject in the supine position by venipuncture or via an intravenous.
catheter placed in an antecubital vein in the arm in ethylenediaminetetraacetic acid containing tubes.
Immediately following collection of the required whole blood volume, the tubes were slowly tilted backwards and forwards (no shaking) to bring the anti-coagulant into solution.
The anticoagulated whole blood stored at room temperature (20-25 °C) was preferably stained within 12 hours, at the latest 24 hours, and analyzed within 24 hours.
The lymphocyte subset counts were analyzed by fluorescence activated cell sorting.
|
10 days
|
Change from baseline to Day 10 in mean CD8+ T-effector cell (CD45RA+/CCR7-) lymphocyte count
大体时间:10 days
|
For each assessment, 1.5 mL of blood was collected aseptically from the subject in the supine position by venipuncture or via an intravenous.
catheter placed in an antecubital vein in the arm in ethylenediaminetetraacetic acid containing tubes.
Immediately following collection of the required whole blood volume, the tubes were slowly tilted backwards and forwards (no shaking) to bring the anti-coagulant into solution.
The anticoagulated whole blood stored at room temperature (20-25 °C) was preferably stained within 12 hours, at the latest 24 hours, and analyzed within 24 hours.
The lymphocyte subset counts were analyzed by fluorescence activated cell sorting.
|
10 days
|
Change from baseline to Day 10 in mean T-regulatory cell (CD25+/Forkhead box P3 (Foxp3+)) lymphocyte count
大体时间:10 days
|
For each assessment, 1.5 mL of blood was collected aseptically from the subject in the supine position by venipuncture or via an intravenous.
catheter placed in an antecubital vein in the arm in ethylenediaminetetraacetic acid containing tubes.
Immediately following collection of the required whole blood volume, the tubes were slowly tilted backwards and forwards (no shaking) to bring the anti-coagulant into solution.
The anticoagulated whole blood stored at room temperature (20-25 °C) was preferably stained within 12 hours, at the latest 24 hours, and analyzed within 24 hours.
The lymphocyte subset counts were analyzed by fluorescence activated cell sorting.
|
10 days
|
Change from baseline to Day 10 in mean skin-homing T-helper cell (Cutaneous lymphocyte antigen (CLA)+/integrin β7-) lymphocyte count
大体时间:10 days
|
For each assessment, 1.5 mL of blood was collected aseptically from the subject in the supine position by venipuncture or via an intravenous.
catheter placed in an antecubital vein in the arm in ethylenediaminetetraacetic acid containing tubes.
Immediately following collection of the required whole blood volume, the tubes were slowly tilted backwards and forwards (no shaking) to bring the anti-coagulant into solution.
The anticoagulated whole blood stored at room temperature (20-25 °C) was preferably stained within 12 hours, at the latest 24 hours, and analyzed within 24 hours.
The lymphocyte subset counts were analyzed by fluorescence activated cell sorting.
|
10 days
|
Change from baseline to Day 10 in mean gut-homing T-helper cell (CLA-/integrin β7+) lymphocyte count
大体时间:10 days
|
For each assessment, 1.5 mL of blood was collected aseptically from the subject in the supine position by venipuncture or via an intravenous.
catheter placed in an antecubital vein in the arm in ethylenediaminetetraacetic acid containing tubes.
Immediately following collection of the required whole blood volume, the tubes were slowly tilted backwards and forwards (no shaking) to bring the anti-coagulant into solution.
The anticoagulated whole blood stored at room temperature (20-25 °C) was preferably stained within 12 hours, at the latest 24 hours, and analyzed within 24 hours.
The lymphocyte subset counts were analyzed by fluorescence activated cell sorting.
|
10 days
|
Maximum plasma concentration (Cmax) of ACT-128800 on Days 9 and 18
大体时间:18 days
|
Blood samples for pharmacokinetic analysis were taken following drug administration on study Day 9 (Day 3 of the dosing period with 40 mg) and study Day 18 (Day 3 of the dosing period with 100 mg) and Cmax of ACT-128800 was determined by non-compartmental analysis.
|
18 days
|
Area under the plasma concentration-time curve from time 0 to 24 hours (AUC0-24) of ACT-128800 on Days 9 and 18
大体时间:18 days
|
Blood samples for pharmacokinetic analysis were taken following drug administration on study Day 9 (Day 3 of the dosing period with 40 mg) and study Day 18 (Day 3 of the dosing period with 100 mg) and AUC0-24 of ACT-128800 was determined by non-compartmental analysis.
|
18 days
|
Area under the plasma concentration-time curve from time 0 to infinity (AUC0-infinity) of ACT-128800 on Day 18
大体时间:18 days
|
Blood samples for pharmacokinetic analysis were taken following drug administration on study Day 18 (Day 3 of the dosing period with 100 mg) and AUC0-infinity of ACT-128800 was determined by non-compartmental analysis.
|
18 days
|
Time to reach maximum plasma concentration (tmax) of ACT-128800 on Days 9 and 18
大体时间:18 days
|
Blood samples for pharmacokinetic analysis were taken following drug administration on study Day 9 (Day 3 of the dosing period with 40 mg) and study Day 18 (Day 3 of the dosing period with 100 mg) and tmax of ACT-128800 was determined by non-compartmental analysis.
|
18 days
|
Terminal half-life (t1/2) of ACT-128800 on Day 18
大体时间:18 days
|
Blood samples for pharmacokinetic analysis were taken following drug administration on study Day 18 (Day 3 of the dosing period with 100 mg) and t1/2 of ACT-128800 was determined by non-compartmental analysis.
|
18 days
|
合作者和调查者
赞助
调查人员
- 首席研究员:Darren Wilbraham, MBBS, DCPSA、Quintiles Drug Research Unit
研究记录日期
研究主要日期
学习开始
初级完成 (实际的)
研究完成 (实际的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (估计)
研究记录更新
最后更新发布 (估计)
上次提交的符合 QC 标准的更新
最后验证
更多信息
与本研究相关的术语
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.
安慰剂的临床试验
-
City of Hope Medical CenterNational Cancer Institute (NCI)主动,不招人造血和淋巴细胞肿瘤 | 骨髓纤维化 | 慢性淋巴细胞白血病 | 缓解期成人急性髓性白血病 | 骨髓增生异常综合症 | 缓解期成人急性淋巴细胞白血病 | 骨髓增殖性肿瘤 | 慢性期慢性粒细胞白血病,BCR-ABL1 阳性 | 成人淋巴母细胞淋巴瘤 | 加速期慢性粒细胞白血病,BCR-ABL1 阳性 | HLA-A*0201 阳性细胞存在 | 巨细胞病毒感染 | 成人霍奇金淋巴瘤 | 成人非霍奇金淋巴瘤美国
-
Mila (bMotion Technologies)完全的
-
Universidad Autonoma de MadridCentro Universitario La Salle完全的